Ranolazine is an anti-arrhythmic drug that targets voltage-gated sodium channels. Lenaeus et al. present a cryo-EM structure of the cardiac sodium channel bound to ranolazine to demonstrate that this compound acts as a structural clamp that inhibits the channels.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Abriel, H. J. Mol. Cell Cardiol. 48, 2–11 (2010).
Clancy, C. E. et al. J. Physiol. 593, 1331–1345 (2015).
Roden, D. M. Card. Electrophysiol. Clin. 6, 695–704 (2014).
Ragsdale, D. S. et al. Science 265, 1724–1728 (1994).
Horvath, B. et al. Front. Pharmacol. 11, 413 (2020).
Li, Z. et al. Angew. Chem. Int. Ed. Engl. 60, 11474–11480 (2021).
Jiang, D. et al. Cell 180, 122–134 (2019).
Lenaeus, M. et al. Nat. Cardiovasc. Res. https://doi.org/10.1038/s44161-023-00271-5 (2023).
Fuller, H. et al. Heart Rhythm 13, 1679–1686 (2016).
Chakouri, N. et al. Nat. Cardiovasc. Res. 1, 1–13 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Fossier, L., Ben-Johny, M. New insights on cardiac Na channel block by an atypical anti-arrhythmic drug. Nat Cardiovasc Res 2, 494–495 (2023). https://doi.org/10.1038/s44161-023-00284-0
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s44161-023-00284-0
